Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
- Japan to Participate in Global PIII Study of Forxiga for Type 1 Diabetes: AZ
August 25, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- Eli Lilly Files for Psoriasis Treatment Ixekizumab in Japan
August 24, 2015
- Janssen, National Center of Neurology and Psychiatry to Jointly Develop Biomarkers for AD Drug Reminyl
August 24, 2015
- EMA Accepts Application for Once-Weekly Oral Proteasome Inhibitor Ixazomib: Takeda
August 24, 2015
- Lilly Challenges Invalidation Ruling on Evista Usage Patent
August 21, 2015
- Astellas to Adopt One-Rep-for-One-Institution Regime in October
August 21, 2015
- Loxonin Suffers Most in Decrease in No. of Prescriptions Following Introduction of Generic Coefficient: Survey
August 21, 2015
- Announcement: 2015 Asia Pacific Meetings of ISMPP (Beijing on Aug. 30, Tokyo on Sept. 2)
August 20, 2015
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…